IL6 and type 2 diabetes mellitus: Also, mROS level in HSVSMCs from T2DM patients was consistently higher (Figure 4A; p < 0.01, n = 6) after treatments with IL-6/sIL-6Rα, IL-6/sIL-6Rα + ruxolitinib, and ruxolitinib alone when compared with those from non-diabetic control HSVSMCs.